Company Profile
DiaMedica Therapeutics Stock Price, News & Analysis
- Ticker:
- DMAC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
6.67 USD (+1.91%)
Close
Last updated: August 5, 2026
311M USD
Market cap
Why the stock is moving
The latest company update was “DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026”. DMAC changed 1.91% and closed at $6.67 on Aug 5, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
Recombinant Kallikrein Therapy
DiaMedica Therapeutics develops DM199, a recombinant form of human tissue kallikrein intended to restore biological pathways involved in vascular regulation, placental function and tissue perfusion.
Preeclampsia Program
Multiple Phase 2 studies are evaluating DM199 in early-onset preeclampsia. These studies are intended to assess safety, pregnancy prolongation and dose selection for a potential multinational Phase 3 program.
Fetal Growth Restriction
An investigator-sponsored Phase 2 study evaluates whether DM199 can improve placental blood flow and fetal outcomes in pregnancies affected by fetal growth restriction.
Acute Ischemic Stroke
ReMEDy2 is a Phase 2/3 study of DM199 in acute ischemic stroke. The trial is progressing toward an interim analysis based on a prespecified enrollment threshold.
Future catalysts
Updated data from the preeclampsia dose-escalation expansion cohort in the second quarter of 2026.
UK clinical-trial-application filing for the Phase 2 early-onset preeclampsia study in the second quarter of 2026.
First patient dosing in the North American and UK dose-ranging preeclampsia study before year-end 2026.
ReMEDy2 interim analysis in the fourth quarter of 2026.
Additional preeclampsia and fetal-growth-restriction data readouts through the end of 2027.
Recent news
- 01
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
Source: DiaMedica Therapeutics
- 02
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: DiaMedica Therapeutics
- 03
- 04
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
Source: DiaMedica Therapeutics
- 05
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
Source: DiaMedica Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of DiaMedica Therapeutics (DMAC)?
DiaMedica Therapeutics (DMAC) most recently closed at 6.67 USD, a +1.91% move versus the previous session.
What is the market cap of DiaMedica Therapeutics (DMAC)?
DiaMedica Therapeutics currently has a market capitalization of 311M USD on BioPharmSignal.
What does DiaMedica Therapeutics do?
Recombinant Kallikrein Therapy DiaMedica Therapeutics develops DM199, a recombinant form of human tissue kallikrein intended to restore biological pathways involved in vascular regulation, placental function and tissue perfusion. Preeclampsia Program Multiple Phase 2 studies are evaluating DM199 in early-onset preeclampsia. These studies are intended to...
On which exchange is DMAC stock listed?
DiaMedica Therapeutics (DMAC) is associated with NASDAQ, United States, Biopharma.
What is Recombinant?
Recombinant Kallikrein Therapy DiaMedica Therapeutics develops DM199, a recombinant form of human tissue kallikrein intended to restore biological pathways involved in vascular regulation, placental function and tissue perfusion.
Which conditions is DiaMedica Therapeutics targeting with Recombinant?
Recombinant Kallikrein Therapy DiaMedica Therapeutics develops DM199, a recombinant form of human tissue kallikrein intended to restore biological pathways involved in vascular regulation, placental function and tissue perfusion. Preeclampsia Program Multiple Phase 2 studies are evaluating DM199 in early-onset preeclampsia. These studies are intended to...
How does DiaMedica Therapeutics describe recent progress with Recombinant?
Updated data from the preeclampsia dose-escalation expansion cohort in the second quarter of 2026. UK clinical-trial-application filing for the Phase 2 early-onset preeclampsia study in the second quarter of 2026. First patient dosing in the North American and UK dose-ranging preeclampsia study before year-end 2026. ReMEDy2 interim analysis in the fourth...
What is Kallikrein?
Recombinant Kallikrein Therapy DiaMedica Therapeutics develops DM199, a recombinant form of human tissue kallikrein intended to restore biological pathways involved in vascular regulation, placental function and tissue perfusion.